Anzeige
Mehr »
Samstag, 27.06.2026 - Börsentäglich über 12.000 News
Brasiliens Moment für seltene Erden ist gekommen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40PJ6 | ISIN: US09072U2069 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOADAPTIVES INC Chart 1 Jahr
5-Tage-Chart
BIOADAPTIVES INC 5-Tage-Chart
GlobeNewswire (Europe)
173 Leser
Artikel bewerten:
(1)

BioAdaptives Inc.: BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle

LAS VEGAS, May 06, 2026 (GLOBE NEWSWIRE) -- via IBN - More than 1 in 3 American adults report insufficient sleep - a deficit that research increasingly links to measurable declines in next-day cognitive performance. Yet the supplement industry has focused almost exclusively on the waking hours, leaving the brain's critical overnight recovery window largely unaddressed.

BioAdaptives, Inc. (OTC: BDPT) today announced the launch of MyndRenew, a nighttime dietary supplement formulated to support sleep quality and the brain's natural overnight recovery processes. MyndRenew is the nighttime component of the Company's MyndSystem platform - a first-of-its-kind approach to cognitive support that spans the full 24-hour cycle.

Addressing the Overlooked Half of Cognitive Health

While the market has been saturated with morning stacks and daytime nootropics, the physiological processes that unfold during sleep - cellular repair, memory consolidation, metabolic waste clearance - have received comparatively little attention from supplement developers. MyndRenew was built to change that.

The formulation features 13 ingredients selected from published scientific literature, each included at levels consistent with those evaluated in clinical research. Together, they are intended to support multiple aspects of nighttime physiology:

  • Sleep quality and relaxation pathways
  • The brain's natural overnight maintenance and recovery processes
  • Cellular resilience and mitochondrial energy function
  • Stress response regulation and nervous system balance
  • Antioxidant and neuroprotective activity

Key ingredients include magnesium glycinate, apigenin, PEA, and lion's mane mushroom extract - anchor compounds with established research profiles in sleep quality, stress resilience, and neuroprotection, respectively.

Management Commentary

"We kept hearing from people who were doing everything right during the day - good nutrition, the right supplements, focused work habits - and still feeling mentally sluggish. The answer was often what wasn't being supported at night. MyndRenew was built to close that gap."

- James Keener, Chief Executive Officer, BioAdaptives, Inc.

The MyndSystem Platform: Full-Cycle Cognitive Support

MyndRenew joins MyndMed as the second pillar of the MyndSystem platform, which is designed to align with the brain's distinct demands across the full daily cycle:

  • MyndMed - Daytime formulation designed to support focus, mental clarity, and cognitive endurance during waking hours
  • MyndRenew - Nighttime formulation designed to support sleep quality and the brain's overnight recovery processes

Availability

MyndRenew is available now at www.myndsystem.com, alongside MyndMed and complete MyndSystem information. The Company also provides updates via X (formerly Twitter) at @BioAdaptivesInc

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for human and animal use. Its formulations are rooted in published research across nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, expected benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.

INVESTOR & MEDIA CONTACT

Emily Harrison
Investor Relations, BioAdaptives, Inc.
(702) 703-1233 | info@bioadaptives.com | www.bioadaptives.com
X - @BioAdaptivesInc


© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.